Scarica l'app Stockscreener
12.50
2.57%
-0.33
Pre-mercato:
12.52
0.02
+0.16%
Precedente Chiudi:
$12.83
Aprire:
$12.6
Volume 24 ore:
2.87M
Relative Volume:
2.09
Capitalizzazione di mercato:
$841.75M
Reddito:
$141.31M
Utile/perdita netta:
$-297.87M
Rapporto P/E:
-2.3177
EPS:
-5.3933
Flusso di cassa netto:
$-168.20M
1 W Prestazione:
+21.95%
1M Prestazione:
+80.38%
6M Prestazione:
+84.09%
1 anno Prestazione:
-14.79%
Intervallo 1D:
$12.11
$13.16
Intervallo di 1 settimana:
$9.5401
$13.41
Portata 52W:
$5.37
$17.58
Ginkgo Bioworks Holdings Inc Stock (DNA) Company Profile
Nome
Ginkgo Bioworks Holdings Inc
Settore
Industria
Telefono
(877) 442-5362
Indirizzo
27 DRYDOCK AVENUE, BOSTON
Compare DNA vs VRTX, REGN, MRNA, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DNA
Ginkgo Bioworks Holdings Inc
|
12.50 | 717.85M | 141.31M | -297.87M | -168.20M | -5.3933 |
VRTX
Vertex Pharmaceuticals Inc
|
506.74 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
734.81 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
188.94 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
936.00 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
205.89 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ginkgo Bioworks Holdings Inc Stock (DNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-05-15 | Downgrade | BTIG Research | Neutral → Sell |
| 2024-05-10 | Downgrade | William Blair | Mkt Perform → Underperform |
| 2023-11-14 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-11-09 | Downgrade | BTIG Research | Buy → Neutral |
| 2023-06-02 | Downgrade | Goldman | Neutral → Sell |
| 2023-05-11 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2022-11-29 | Iniziato | Berenberg | Buy |
| 2022-10-04 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-05-18 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-03-02 | Ripresa | Cowen | Outperform |
| 2022-02-23 | Iniziato | Goldman | Neutral |
| 2022-02-01 | Iniziato | BofA Securities | Neutral |
| 2022-01-28 | Iniziato | BofA Securities | Buy |
| 2022-01-07 | Iniziato | BTIG Research | Buy |
| 2021-11-29 | Iniziato | Jefferies | Buy |
| 2021-10-13 | Iniziato | Raymond James | Outperform |
| 2021-10-12 | Iniziato | William Blair | Outperform |
| 2021-09-20 | Iniziato | HSBC Securities | Buy |
Mostra tutto
Ginkgo Bioworks Holdings Inc Borsa (DNA) Ultime notizie
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Ginkgo Bioworks: Another Curious Rally (NYSE:DNA) - Seeking Alpha
AbbVie and Takeda can use AI models without revealing sequences to other members - Stock Titan
(DNA) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
AI-Driven Innovation Reshapes Vaccine Adjuvant Discovery as Investment Surges Across Public and Private Sectors - GlobeNewswire Inc.
Everpure, Fervo Energy, Charles River Laboratories And Other Big Stocks Moving Higher On Thursday - Benzinga
Ginkgo Bioworks Holdings, Inc. (DNA) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Yahoo Finance
Ginkgo Bioworks (DNA) Surges 11.1%: Is This an Indication of Further Gains? - Yahoo Finance
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Analysis: Navigating Challenges in the Biotech Sector - DirectorsTalk Interviews
Ginkgo Bioworks (DNA) officer may sell 2,200 shares - Stock Titan
Ginkgo Bioworks Holdings, Inc. (DNA) Rises As Market Takes a Dip: Key Facts - finance.yahoo.com
Ginkgo Bioworks (NYSE: DNA) director sells 5,000 shares near $7.08 - Stock Titan
Ginkgo Bioworks And Eli Lilly And Company Enter Partnership To Integrate Ginkgo Datapoints With Lilly TuneLab - marketscreener.com
Ginkgo Datapoints Announces Partnership with TuneLab to Close the Gap between AI Models and Lab Data - Investing News Network
Twist Bio, and Ginkgo rise after agreements with Lilly TuneLab (TWST:NASDAQ) - Seeking Alpha
(DNA) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Director plans potential 5,000-share sale at Ginkgo Bioworks (NYSE: DNA) - Stock Titan
Up to $17.5M awarded to Ginkgo for medicines made for one patient - Stock Titan
Ginkgo Bioworks Joins ARPA-H GIVE Program to Build Autonomous Manufacturing System for Individualized RNA Medicines - Investing News Network
BTIG cuts Ginkgo Bioworks stock price target on transition concerns By Investing.com - Investing.com Nigeria
DNAGinkgo Bioworks Holdings Inc Earnings - Finviz
BTIG cuts Ginkgo Bioworks stock price target on transition concerns - Investing.com
Ginkgo Bioworks Holdings Inc (DNA) PT Lowered to $5 at BTIG - StreetInsider
BTIG Maintains Ginkgo Bioworks(DNA.US) With Sell Rating, Maintains Target Price $5 - Moomoo
BTIG reiterates Ginkgo Bioworks stock Sell rating at $5 target By Investing.com - Investing.com Canada
BTIG reiterates Ginkgo Bioworks stock Sell rating at $5 target - investing.com
BTIG Reiterates Sell Rating on Ginkgo Bioworks Holdings Inc (DNA) - StreetInsider
Ginkgo Bioworks: Another Pivot, Still No Proof Of Product-Market Fit (NYSE:DNA) - Seeking Alpha
Ginkgo Bioworks Holdings Inc. Class A (DNA) Peer Comparison – Compare with Others - Value Research
DNA Q2 2026 Earnings: Narrower-Than-Expected Loss Beats Estimates, Stock Still Slides 3.23%Long-Term Guidance - careplusvn.com
Ginkgo Bioworks Holdings Inc (DNA) Financials FY2025: Revenue $170.2M, Net Loss $313K - Stock Titan
Ginkgo Bioworks (DNA) Declines 4.13% as Shares Approach Critical $6.61 SupportRating Change - siam.in
Ginkgo Bioworks CFO Steven Coen sells $2,302 in stock By Investing.com - Investing.com Nigeria
Ginkgo Bioworks CFO Steven Coen sells $2,302 in stock - Investing.com
Ginkgo Bioworks (DNA) officer to sell 330 shares for taxes after vesting - Stock Titan
Ginkgo (DNA) Price: Posts a 6.32% Gain to $7.40 for the Current Session; Market Levels: the Near-Term Reference Band Stretches From $7.03 to $7.77 in the Current UpdateVolume Rate Change - careplusvn.com
Ginkgo Bioworks (NYSE:DNA) Shares Gap UpHere's Why - MarketBeat
Ginkgo Bioworks (NYSE:DNA) Upgraded to Hold at Zacks Research - MarketBeat
Estee Lauder, Moderna, Merck And Other Big Stocks Moving Higher On Wednesday - Benzinga
Ginkgo Bioworks (NYSE: DNA) insider plans 2,200-share sale - Stock Titan
How Ginkgo Bioworks Holdings Inc. Class A (DNA) Affects Rotational Strategy Timing - Stock Traders Daily
Ginkgo Bioworks (DNA) Slides 6.22% as Shares Approach Key SupportEntry Point Alerts - vinanet.vn
These Analysts Think Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Sales Are Under Threat - Moomoo
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Analysts Just Slashed This Year's Revenue Estimates By 22% - simplywall.st
Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (JANX) and Ginkgo Bioworks Holdings (DNA) - The Globe and Mail
Ginkgo Bioworks Holdings, Inc. (DNA) Q2 2026 Earnings ReportResults, Call & Slides - TipRanks
William Blair Maintains Ginkgo Bioworks(DNA.US) With Sell Rating - Moomoo
Ginkgo Bioworks Holdings Inc (DNA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Ginkgo Bioworks (DNA) Sheds 3.33% as Shares Approach Critical $6.9 SupportStock Buy Zone - vinanet.vn
Ginkgo Bioworks Holdings Inc Azioni (DNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.48%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):